초록 ▼

A specialized drug delivery unit for inner ear treatment which employs a portion of carrier media material containing one or more therapeutic agents therein. The carrier media material is designed to release the therapeutic agents in a controlled manner over time. The drug delivery unit is sized for

A specialized drug delivery unit for inner ear treatment which employs a portion of carrier media material containing one or more therapeutic agents therein. The carrier media material is designed to release the therapeutic agents in a controlled manner over time. The drug delivery unit is sized for placement in the round window niche of a patient. The released therapeutic agents come in contact with the round window membrane and pass therethrough into the inner ear for treatment purposes. This system provides many benefits ranging from the ability to deliver drugs in a site specific, highly controlled manner to the transfer of such materials with minimal patient discomfort and monitoring requirements.

대표청구항 ▼

1. A method for delivering a therapeutic agent into the inner ear of a living subject, said method comprising: providing a drug delivery unit comprising a carrier material and a therapeutic agent combined therewith, wherein said carrier material provides for controlled release of the therapeutic age

1. A method for delivering a therapeutic agent into the inner ear of a living subject, said method comprising: providing a drug delivery unit comprising a carrier material and a therapeutic agent combined therewith, wherein said carrier material provides for controlled release of the therapeutic agent from said drug delivery unit over time, and further wherein said drug delivery unit is configured as a pellet, disk, tablet, plate, sphere, cube, cylindrical unit, or strand, andsaid drug delivery unit is shaped and sized for partial or complete insertion into the round window niche of the subject; andinserting said drug delivery unit directly into the round window niche of the subject such that said unit is positioned either partially or completely within the round window niche, wherein the therapeutic agent is released from the drug delivery unit, contacts the round window membrane and passes into the inner ear. 2. The method of claim 1, wherein said therapeutic agent is released over a period of 24 hours. 3. The method of claim 1, wherein said therapeutic agent is released over a period of hours. 4. The method of claim 1, wherein said therapeutic agent is released over a period of months. 5. The method of claim 1, wherein said carrier material comprises a polymer. 6. The method of claim 1, wherein said therapeutic agent is selected from the group consisting of urea, mannitol, sorbitol, glycerol, lidocaine, xylocaine, epinephrine, immunoglobulins, sodium chloride, steroids, heparin, hyaluronidase, aminoglycoside antibiotics, antioxidants, neurotrophins, nerve growth factors, various therapeutic peptides, and polysaccharides. 7. The method of claim 6, wherein the therapeutic agent is an aminoglycoside antibiotic. 8. The method of claim 7, wherein the aminoglycoside antibiotic is gentamycin. 9. The method of claim 1, wherein said drug delivery unit is shaped and sized for complete insertion into the round window niche of the subject. 10. The method of claim 1, wherein said drug delivery unit is shaped and sized for partial or complete insertion as a detached unit into the round window niche of the subject. 11. The method of claim 10, wherein said drug delivery unit is shaped and sized for complete insertion as a detached unit into the round window niche of the subject. 12. The method of claim 10, wherein said drug delivery unit is positioned at a location which is spaced apart from the round window membrane. 13. The method of claim 1, wherein said drug delivery unit has a volume of between 0.1 mm3 and 250 mm3. 14. The method of claim 1, wherein said carrier material is capable of delivering the therapeutic agent to the inner ear in nanogram to microgram quantities. 15. The method of claim 1, wherein said therapeutic agent is present in a quantity of between about 10 wt % and 40 wt % of the total weight of the drug delivery unit. 16. The method of claim 1, wherein said carrier material comprises a polyanhydride material. 17. The method of claim 1, wherein said carrier material comprises a polyorthoester material. 18. The method of claim 1, wherein said carrier material comprises hydroxypropylmethyl cellulose. 19. The method of claim 1, wherein said carrier material comprises hydroxyethyl cellulose. 20. The method of claim 1, wherein said carrier material comprises hydrophilic microspheres. 21. The method of claim 1, wherein said carrier material comprises a bioadhesive material. 22. The method of claim 1, wherein said drug delivery unit is a multiphased composite drug delivery unit. 23. The method of claim 1, wherein said release of said therapeutic agent is achieved by osmosis, diffusion, active/passive transport, or a combination thereof. 24. The method of claim 1, wherein the carrier material is biodegradable. 25. The method of claim 1, wherein the carrier material is synthetic. 26. The method of claim 1, wherein release of the therapeutic agent from the drug delivery unit is without inadvertent delivery to other tissue regions outside the round window niche.